- Home
- RBNE vs INTS Comparison
RBNE vs INTS Comparison
Compare RBNE & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBNE
- INTS
- Stock Information
- Founded
- RBNE 2024
- INTS 2012
- Country
- RBNE Cyprus
- INTS United States
- Employees
- RBNE N/A
- INTS N/A
- Industry
- RBNE Marine Transportation
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- RBNE Consumer Discretionary
- INTS Health Care
- Exchange
- RBNE Nasdaq
- INTS Nasdaq
- Market Cap
- RBNE 7.3M
- INTS 8.4M
- IPO Year
- RBNE N/A
- INTS 2023
- Fundamental
- Price
- RBNE $1.99
- INTS $0.30
- Analyst Decision
- RBNE
- INTS Strong Buy
- Analyst Count
- RBNE 0
- INTS 4
- Target Price
- RBNE N/A
- INTS $4.50
- AVG Volume (30 Days)
- RBNE 498.0K
- INTS 5.8M
- Earning Date
- RBNE 09-02-2025
- INTS 08-07-2025
- Dividend Yield
- RBNE N/A
- INTS N/A
- EPS Growth
- RBNE N/A
- INTS N/A
- EPS
- RBNE N/A
- INTS N/A
- Revenue
- RBNE N/A
- INTS N/A
- Revenue This Year
- RBNE N/A
- INTS N/A
- Revenue Next Year
- RBNE N/A
- INTS N/A
- P/E Ratio
- RBNE N/A
- INTS N/A
- Revenue Growth
- RBNE N/A
- INTS N/A
- 52 Week Low
- RBNE $1.63
- INTS $0.19
- 52 Week High
- RBNE $20.57
- INTS $4.35
- Technical
- Relative Strength Index (RSI)
- RBNE N/A
- INTS 49.95
- Support Level
- RBNE N/A
- INTS $0.28
- Resistance Level
- RBNE N/A
- INTS $0.32
- Average True Range (ATR)
- RBNE 0.00
- INTS 0.03
- MACD
- RBNE 0.00
- INTS 0.01
- Stochastic Oscillator
- RBNE 0.00
- INTS 78.80
About RBNE Robin Energy Ltd. Common Stock
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.